A platform for superior delivery of drugs to the lungs to treat bacterial pneumonia.
For investing and partnering opportunities contact us
"Researchers hope that delivering medicines directly to the lungs can exploit those characteristics and make drugs that are more efficient and effective than oral or injectable drugs—and maybe easier to take." (Mosenbergen)
"Beyond Asthma: Designing Inhaled Drugs to Fight More Diseases" April 2023
Impaired lungs interfere with uniform drug delivery required for enhanced treatment efficacy and consistency.
BLTx liquid delivery platform facilitates homogeneous distribution in the lung by expanding impaired lungs while supporting oxygen exchange.
The BLTx liquid delivery system is highly adaptable, enabling the delivery of a variety of therapeutics.
This flexibility allows for tailored therapies to address diverse lung diseases, including cancer and infections.
BL Therapeutics is a pre-clinical stage biotechnology company advancing delivery of drugs and biologics to the lung. Our studies demonstrate that the liquid platform can effectively deliver pharmaceuticals, proteins and nucleic acids directly to the lung. This platform has the potential for differentiated efficacy and dosing in the treatment of bacterial and viral pneumonia, asthma, lung cancer and other lung diseases.
